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Summary.-Immunofluorescent assessment of hormone receptors in melanocytic
tumours is quite feasible without loss of diagnostic material, in contrast to the
impracticability of quantitative biochemical assays. Using this method, oestrogen
receptors were demonstrated in 4/6, and progesterone receptors in 3/5 patients with
metastatic melanoma. Receptors were not found in 3 patients with primary cutaneous
melanomas of the superficial spreading type. Progesterone receptors were present
in the junctional component of a naevus from one healthy person.
ALTHOUGH THERE IS apparently no sex
difference in the incidence of malignant
melanoma, Shaw et al. (1978) found that
prognosis and survival favoured women of
child-bearing age. They also concluded
that the disease may have a capacity to
metastasize more slowly in women and
that the sites of primary lesions are dif-
ferent in men and women. The data of
Shiu et al. (1976) strongly suggested an
adverse influence of pregnancy on women
with Stage II melanoma. These observa-
tions, in conjunction with the rarity of
prepubertal melanomas, suggest that the
developmental and clinical behaviour of
malignant melanoma may be influenced
by the hormonal status of the individual.
This inference is supported by evidence of
activation ofmelanoma by the administra-
tion of oestrogens (Sadoff et al., 1973) and
by a specific oestrogenic effect in some
melanoma patients who responded to 6a-
methyl-pregnenetrione which has anti-
oestrogen and weak glucocorticoid proper-
ties (Johnson et al., 1966). Conversely,
therapeutic responses have been noted
with oestrogen (Fisher et al., 1978) and
with oestrogen linked to nitrogen mustard
(Didolkar et al., 1978).
A mechanism by which oestrogen could
affect melanoma cells has been suggested
by the demonstration of oestrogen and
progesterone receptors estimated bio-
chemically in cytosol homogenates, by a
number of groups (Fisher et al., 1976,
1978; Kokoschka et al., 1979; Chaudhuri
et al., 1980; Rumke et al., 1980). Since
knowledge of the hormone-receptor status
of melanoma tumours could have impor-
tant therapeutic implications, were it
possible to extrapolate from the successful
outcome of endocrine therapy in a propor-
tion of receptor-bearing breast cancers
(McGuire et al., 1978), we felt that these
biochemical results justified further in-
vestigation.
Quantitative biochemical methods are
not always applicable to malignant
melanoma, especially in primary tumours,
since they are usually too small for part of
the tumour to be spared for separate assay.
Methods of demonstrating oestrogen (RE)
and progesterone receptors (RP) in breast-
cancer cells by indirect immunofluorescent
techniques have been developed by several
laboratories (Mercer, 1978; Pertschuk et
al., 1978; Nenci et al., 1978). For breast
carcinoma, Pertschuk et al. were able to
show a statistically significant agreement
for their positive findings, between RE
demonstrated by indirect immunofluores-
cence and RE detectedby theconventionalHORMONE RECEPTORS IN MELANOCYTIC TUMOURS
dextran-charcoal biochemical assay. In
the present study, we have overcome the
problems inherent in the assessment of
hormone receptors in small tumours, by
applying immunofluorescent methods
similar to those developed for carcinoma of
the breast, on the melanocytic tumours in
our series. We have confirmed the findings
from the cytosol assays. This paper reports
our preliminary results.
PATIENTS
The details of the melanoma patients are
given in the Table. The naevi were removed
from persons without melanoma.
MATERIALS AND METHODS
Handling of specimens-.Tumour speci-
mens were examined and dissected within
seconds of excision in the theatre suite, and
representative blocks for immunofluorescent
receptor assay immediately snap-frozen in
liquid N2. The rest of the specimen was pro-
cessed for histological diagnosis. When the
tumour was of sufficient size, tissue was also
taken for biochemical assay of hormone
receptors.
Immunofluorescent techniques -Specimens
were stored at -70°C and examined within
3 days oftheir excision. Four-micron sections
were cut in a cryostat at - 20°C on to gelatin-
coated slides, dried in air for 10-15 sec and
stored in the cryostat until sectioning was
completed. They were then processed im-
mediately by the method of Mercer (1978).
Using this method, the sections were ineu-
bated in Coplin jars containing 10-6M
oestradiol or progesterone for 2 h at 4C in
Krebs-Ringer-Henseleit glucose buffer con-
taining 10% normal pooled human serum; they
werethen fixed for 10minatroom temperature
(RT) by transferring the slides to other
Coplin jars containing a 10% solution of para-
formaldehyde in PBS. After w,ashing in a
bath of PBS for 10 min at RT with gentle
agitation, the sections were treated with 10%
normal rabbit serum for 10 min at RT to
reduce nonspecific staining. Excess serum
was removed by aspiration. This step was
followed by incubation for 40 min at RT with
sheep anti-oestradiol serum or anti-pro-
gesterone serum diluted 1/10, after which the
sections were washed in PBS for 15 min and
finally treated with FITC-conjugated rabbit
anti-sheep globulins (Welleome) diluted 1/20,
for 40 min at RT. After a final wash, the
preparations were counterstained with 0 02%
eriochrome black and mounted in phosphate-
buffered glycerol. Great care was taken to
keep the sections moist during the successive
processing steps.
The anti-hormone sera were produced in
sheep by immunization with oestradiol
17/3-6 CMO-BSA or progesterone Ila-hemi-
succinate-BSA in Freund's complete adju-
vant. They were tested for specificity against
a variety of chemically related steroids in the
following way: a standard curve was estab-
lished from the results obtained by incu-
bating varying amounts of unlabelled specific
hormone, in the range 12-5-500 pg, with a
fixed amount (of the order of 10 nCi) of
specific (3H-) hormone, in the presence of a
standard volume of antiserum appropriately
diluted on the basis of its predetermined titre
(Cox et al., 1979). At the same time, varying
amounts of unlabelled potentially cross-
reacting steroids from 25 pg to 100 ng were
reacted as for the standard curve procedure
and compared with results for the measure-
ments with the homologous hormone. The
percentage cross-reactivity was calculated as
described (Abraham, 1969). The cross-reac-
tion of the anti-oestradiol serum was below
1% with oestrone or oestriol, and below 0.10%
with testosterone, androstenedione, pro-
gesterone, 17a-hydroxy progesterone and
cortisol. The cross-reaction of the anti-
progesterone serum was below 1% with 17a-
hydroxy-progesterone and pregnenolone, and
below 0-1% with cortisol.
The following controls were included for
each specimen: incubation of sections with
normal sheep serum in place of sheep anti-
hormone sera to detect nonspecific binding of
serum; incubation with PBS in place of anti-
hormone serum to detect nonspecific binding
of the fluorescein conjugate; incubation with
PBS in place of hormone solution to detect
the presence of endogenous hormone fixed to
receptors. Other controls were the use ofanti-
hormone sera absorbed with specific hormone,
competitive-binding tests of the RE reaction
by coincubation with oestradiol and 10-4M
diethyl silboestrol or nitromifene citrate, the
absence of a significant reaction with FITC-
conjugated goat anti-rabbit globulins and the
absence of a reaction with receptor-negative
tissue (human muscle). Results of concurrent
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studies with breast tumours had proved the
efficacy of the antisera before we started this
project.
The stained sections were examined with a
Leitz Ortholux microscope fitted with Ploem
epi-illumination, an HB200 mercury lamp as
a light source, dichroic mirrors on Position 3
and BG38 and K510 filters. The receptor-
positive cells were assessed visually by
examination of 2-4 serial sections cut at each
of 2 specimen levels. The average percent-
ages of positive cells in the tumour popula-
tion in the sections were subjectively graded
by one of us (A.J.T.) for each specimen, on
the following basis: <10%: +; 10%-25%:
1+;25%-50%:2+;50%-75%:3+; >75%:
4+.
Biochemical assay of tumour cytosols.
Three of the specimens were large metastases
of malignant melanoma, so that sufficient
tissue was available for biochemical assay of
RE and RP, as well as morphological assess-
ment. In one smaller sample, only tissue for
RE assay could be spared for testing. The
methods described by Hawkins et al. (1975)
and Pichon & Milgrom (1977) were used, with
R5020 as a progesterone substitute.
RESULTS
Pathology of tumours
Tumours from 13 patients were exam-
ined. Six of these were metastatic malig-
nant melanomas, 3 primary cutaneous
malignant melanomas, 3 benign compound
naevi and 1 benign intradermal naevus.
Biochemical assays
Analysis of the tumour cytosols in the
4 patients tested for RE showed 3 posi-
tive. Of the 3 patients tested for RP 2
were positive. The receptor values are
given in the Table. In Patients 1 and 4,
2 metastatic nodules were available for
study: there was a variation in the detect-
able quantity of receptors between the
2 nodules, for both patients.
Immunofluorescent demonstration of hor-
mone receptors
Malignant melanomas.-Four (1 female,
3 male) of 9 patients had RE and 3 (1
female, 2 male) of 7 had RP (see Table).
The receptors were located mainly in the
cytoplasm (Fig. 1). In the positive tu-
mours, very slight traces of "endogenous"
oestrogen and progesterone were some-
times seen, but this may have been attri-
butable to small quantities of hormone in
the human serum pool used in the incuba-
tion buffer (oestrogen, 55 pg/ml; proges-
terone, < 500 pg/ml).
All the positive reactions occurred in
patients with metastatic nodules. Their
graded reactions for percentages of re-
ceptor-positive cells are shown in the
Table. The receptor-bearing cells usually
occurred fairly randomly throughout the
examined area of the tumour section. But
in Patient 4 they were present in distinct
clusters (Fig. 1) juxtaposed to areas
devoid of receptor-bearing cells. The 2
nodules from Patient 4 differed from each
other in their percentage of receptor-
positive cells.
In the 4 patients (1, 4, 5, and 6) in whom
both immunofluorescent and biochemical
tests were applied, the tumours showed
consistent results for the presence of
receptors by both assays, except for
nodule (2) from Patient 1 and nodule (1)
from Patient 4.
InthetumourfromPatient5,inaddition
to a reaction for cytoplasmic oestradiol
binding, immune-reactive hormone was
frequently found in perinuclear rings in
the same cells (Fig. 2).
Benign naevi.-A compound naevus
from Patient 10 showed cytoplasmic RP
in a group of larger "junctional" cells in
the papillary dermis and junctional zone,
but the smaller intradermal melanocytic
cells were quite negative (Fig. 3). The
other naevi were without demonstrable
receptors.
DISCUSSION
For a satisfactory histological assess-
ment ofsmall melanocytic tumours, which
in itself can be difficult, the whole speci-
men should be available for histology. We
believe we have solved the technical prob-
lems of assessing their receptor status by
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Fia.G 1.-Progesterone receptors (RP) detected by the immunofluorescent technique in the cytoplasm
of melanoma cells from Patient 4. About 75% of the cells in this section were positive; they
occurred in clusters in restricted areas. x 300
FIG. 2.-Oestradiol binding demonstrated in both cytoplasm, and perinuclear rings of the same
melanoma cells, from Patient 5. Four such cells are seen in the lower right quadrant of the photo-
graph. x 320
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the application of a morphological tech-
nique. With this procedure, it is possible
to test for severaiM receptors (e.g., oestro-
gen, progesterone, androgen and gluco-
corticoid receptors) in one sample. The
advantages to be gained from the use of
morphological methods are becoming in-
creasingly evident from the recent pub-
lications on breast cancer (Pertschuk
et al., 1978; Lee, 1980). With such a histo-
chemical technique as ours, the localiza-
tion of the receptor-positive cells within
the tumour and the receptors within the
cells can be assessed. Possibly microsomal
(Watson & Muldoon, 1977) and lysosomal
(Szego, 1974) receptors which cannot be
detected in the cytosol assay are included
in the cytoplasmic steroid-binding sites
(a-)
(b))
FIG. 3.
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FIG.-.3(c). .
Fia. 3.-A campaund na3va3 from Patient 10 showing cytoplasmic RP in a clearly demarcated
superficial focus ofna3vus cells. Receptors were not detected in the smaller cells in the deeper aspect
of the naevus. (a) and (b) by immunofluore3cence-(a) x 200, (b) x 320. (c) Light microscopy.
H. & E. x 150
demonstrated by our method. Addition-
ally, the binding of hormones to plasma
steroid-binding proteins and receptors
related to all the extractable cell proteins
are 2 shortcomings of the cytosol assay
which an immunomorphological approach
avoids.
We have shown that 4/9 patients with
malignant melanoma had RE and 3/7
patients had RP. Ofthe 7 cases where tests
for RE and RP were performed, they were
positive for both in 2, for RE in 1, and
for RP in 1. In the 4 patients tested by
immunofluorescent and biochemical
methods, there was agreement between
both assays, with 2 exceptions (Patient
1, nodule (2) and Patient 4, nodule (1)). In
nodule (2) of Patient 1, the sections were
negative for RE by the immunofluorescent
technique, but the portion ofthe specimen
sent for biochemical assay was found to
contain 8 fmol RE/mg cytosol protein. In
this nodule there would have been only a
small minority of cells with RE and there
could have been a dearth of receptor-
positive cells at the 2 levels of the speci-
men tested by immunofluorescence. The
discrepancy in the results for nodule (1)
of Patient 4 is discussed in the following
paragraph.
Besides binding to RP, progesterone also
binds to androgen and glucocorticoid re-
ceptors (Horwitz et al., 1975; Ojasoo &
Raynaud, 1978); the positive immuno-
fluorescent reactions for RP seen in our
tests possibly represent a summation of
the reactions with all 3 receptors. This
could be an explanation for the high pro-
portion of immunofluorescent RP+ cells
in the 2 nodules from Patient 4, com-
pared with the negative orlow (15 fmol/mg
protein) values detected by biochemical
assay (Table). We are proceeding to
elucidate the specificity of the progester-
one reactions by competitive-binding
studies, and by testing tumours with
antisera specific for androgen and gluco-
corticoidhormones.
The presence of hormone receptors in
melanoma has not so far been shown to
correlate with clinical responses to endo-
crine manipulation (Fisher et al., 1978;
Creagan et al., 1980; Papac et al., 1980;
Rumke et al., 1980). Results from a trial by
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Karakousis et al. (1980) were equivocal.
Although Papac et al. did not specify their
receptor values, the levels detected by the
other groups were generally quite low.
At the Royal Adelaide Hospital anid
Flinders Medical Centre, oestrogen-bind-
ing activity by breast cancers ofmore than
70 fmol/mg is considered the clinically
positive threshold, above which the chan-
ces of a response to hormone manipulation
are greatly increased (Dr E. Cant, personal
communication). If similar criteria are
applied to the metastases from our 4
melanoma patients for which biochemical
assays were performed by the same South
Australian laboratory, all these tumours
should be regarded as RE-. This raises an
important implication in prognostic and
therapeutic studies, as the levels of recep-
tor-binding activity regarded as clinically
positive by other groups (Fisher et al.,
1976; Karakousis et al., 1980; Rumke
et al., 1980) were much lower than ours.
It is therefore important in such studies
that the criteria of receptor-binding acti-
vity be carefully defined.
Although accurate quantitation of re-
ceptors is not possible with the immuno-
fluorescent method, semiquantitation by
estimation of the proportion of receptor-
positive cells should be possible. In our
ongoing studies on melanomas, we intend
to compare the gradings for receptor-
positive cells present with the biochemical
assay values. Using his immunofluorescent
technique which we have followed here,
Mercer (1 978) found that breast-cancer
tumours whose cell population contained
5000 of RE+ cells, had a cytosol con-
tent of 100 fmol/mg. Estimation of the
proportion of receptor-positive cells in
the tumour could be valuable from a
therapeutic point of view, assuming that
receptor-positive cells in melanoma are
hormone-dependent, and a significant pro-
portion ofsuch cells is needed for oestrogen
to sustain tumour growth. From their
tabulated data, several of the melanoma
patients in the study of Chaudhuri et at.
(1980) would have had cytosol RE levels
regarded by us as being clinically positive
and potentially treatable by endocrine
therapy, if comparison can be made with
breast-cancertrials; the tumours may have
contained numbers of RE+ cells in excess
of, or approaching the numbers of RE-
cells. In addition to the Chaudhuri et al.
patients, one of ours (No. 2) had > 5000
tumour cells RE+. Quite possibly, by
choosing patients such as these on the
basis of the proportion of tumour RE+
cells, a better selection of melanoma sub-
jects as suitable candidates for endocrine
therapy could be made.
The significance of our results awaits
further investigation. It is too early for
us to assess the clinical responses in several
ofthe patients in this study who are und(ler-
going hormone treatment.
It has been suggested that defects in the
interaction of receptor and hormone, and
their translocation, may account for varia-
tions in the outcome ofhormone therapy of
breast cancer (McGuire et al., 1978). There
may be impairment of the translocation
of the receptor-hormone complex to the
nucleus. We suggest that the perinuclear
rings of immune-reactive oestradiol in
Patient 5 may indicate a defect in the
access to the nucleus ofreceptor-oestradiol
complexes across the nuclear membrane
(Nenci et al., 1978). Since the presence of
RP is considered to be a phenotypic
expression of effective osetrogen action,
their absence from Patient 5 may have
been due to a failure of cytosol-to-nucleus
transport. Knowledge ofsuch a defect may
assist in predicting tumour behaviour
and response to therapy.
We have found that 5/6 metastatic
melanomas carried hormone receptors. On
the other hand, the 3 primary cutaneous
melanomas were negative for both RE
and RP, though RP was not tested for in
one case. All the primary melanomas were
of the superficial spreading type. Two
showed early invasion (Level II) to a
depth of 0-46 mm and 0 94 mm respec-
tively, and the third showed invasion of
the reticular dermis (Level IV) to a thick-
ness of 2-73 mm. It would be interesting
to ascertain whether receptors are always
651652 A. J. THOMPSON, M. G. COOK AND P. G. GILL
absent in superficial spreading melano-
mas, and whether they are present in
other types of melanoma. As they were
present in all but one of the metastatic
melanomas, one could speculate that the
presence ofreceptors may be an indication
of metastatic potential. Clearly, many
more cases need to be studied.
The differential diagnosis ofsome benign
melanocytic naevi from malignant mela-
noma is often problematical. Indeed it is
assumed that at least some melanomas
arise from naevi. For these reasons we
have tested for hormone receptors in 4
benign naevi. All were negative, except
that the junctional component of one
compound naevus contained RP. Oestro-
gen-binding in a significant proportion
of benign naevi from patients with mela-
noma has been reported elsewhere (Chaud-
huri et al., 1980); none was found by that
group in naevi from patients without
melanoma. Our 4 patients did not have
detectable melanoma. In view of the
observations of Chaudhuri et al., our posi-
tive finding suggests that the existence of
hormone receptors in naevi could be an
indicator of predisposition to malignancy.
Again further cases relating to this aspect
of our work need to be documented.
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